Telehealth Integrated Care Model in Patients With Cardiometabolic Disease
Evaluation of the Telehealth Integrated Care Model in Patients With Hyperlipidemia and Other Cardiometabolic Disease
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Lequn Zhou, Dr
- Phone Number: +86 1082266280
- Email: zhoulequnde@126.com
Study Contact Backup
- Name: Yipei Wang, Ph.D
- Phone Number: +86 1082266191
- Email: yipeiw@126.com
Study Locations
-
-
Beijing
-
Beijing, Beijing, China
- Recruiting
- Peking University Third Hospital
-
Contact:
- Lequn Zhou
- Email: zhoulequnde@126.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Age ≥ 16 years, and ≤ 85 years;
- Diagnosis as hyperlipidemia with at least one of the following disease: hypertension or type 2 diabetes mellitus;
- Agreed to be enrolled in this study.
Exclusion Criteria:
- Undergone percutaneous coronary intervention within one year in our hospital;
- Severe LV dysfunction, such as LV ejection fraction < 35%, or congestive heart failure with New York Heart Association (NYHA) functional class IV or Killip class IV;
- Structural heart disease, or severe arrhythmia;
- Severe liver or kidney diseases, endocrinology diseases, hematologic diseases, rheumatic immune system diseases, and malignancy;
- could not complete at least one-year-followup.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Telehealth Integrated Care Group
Followed up in online Internet hospital, estimated and adjusted treatment accroding to clinical efficacy, and send individualized health education messages regularly.
|
Followed up in online Internet hospital, estimated and adjusted treatment accroding to clinical efficacy, and send individualized health education messages regularly.
|
|
Conventional Group
Followed up face-to-face in cardiacmetabolic clinics, estimated and adjusted treatment accroding to clinical efficacy, and conducted health education.
|
Followed up face-to-face in cardiacmetabolic clinics, estimated and adjusted treatment accroding to clinical efficacy, and conducted health education.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
changes of compliance rate of target treatment for hyperlipidemia
Time Frame: 12 month after recuitment
|
difference of compliance rate of target treatment for hyperlipidemia between endpoint with baseline
|
12 month after recuitment
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
changes of blood pressure
Time Frame: 12 month after recuitment
|
difference of blood pressure(both systolic and diastolic blood pressure will be measured.)
between endpoint with baseline
|
12 month after recuitment
|
|
changes of glycosylated hemoglobin
Time Frame: 12 month after recuitment
|
difference of glycosylated hemoglobin between endpoint with baseline
|
12 month after recuitment
|
|
changes of fasting glucose
Time Frame: 12 month after recuitment
|
difference of fasting glucose between endpoint with baseline
|
12 month after recuitment
|
|
changes of LDL-c
Time Frame: 12 month after recuitment
|
difference of LDL-c between endpoint with baseline
|
12 month after recuitment
|
|
changes of triglyceride
Time Frame: 12 month after recuitment
|
difference of triglyceride between endpoint with baseline
|
12 month after recuitment
|
|
abnormal liver function
Time Frame: 12 month after recuitment
|
an increase above the 3-fold normal value for ALT or AST.
|
12 month after recuitment
|
|
abnormal kidney function
Time Frame: 12 month after recuitment
|
an increase in creatinine of ≥ 30%
|
12 month after recuitment
|
|
Rehospitalization
Time Frame: 12 month
|
Rehospitalization because of coronary heart disease, poor blood pressure control, and poor glycemic control
|
12 month
|
|
Cardiovascular death
Time Frame: 12 month
|
Death because of cardiovascular diseases and sudden death
|
12 month
|
|
medication adherence rate
Time Frame: 12 month
|
Difference of medication adherence between each group measured by Morisky Medication Adherence Scale-8
|
12 month
|
|
patients satisfaction
Time Frame: 12 month
|
patients will be asked to rate their satisfaction score in Likert form with 1 being the most unsatisfactory and 5 being the most satisfactory on the overall experience, the medical diagnosis process, service attitude and physician's professionalism.
|
12 month
|
|
medical cost
Time Frame: 12 month
|
Health Economics on medical cost, transportation cost, accommodation cost, waiting time and lost work time
|
12 month
|
|
in person visit counts
Time Frame: 12 month after recuitment
|
total number of in person visits
|
12 month after recuitment
|
|
telehealth visit counts
Time Frame: 12 month after recuitment
|
total number of telehealth visits
|
12 month after recuitment
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Lin Zeng, Ph.D, Peking University Third Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- PekingUTH Telehealth
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.